ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2019) 63 P577 | DOI: 10.1530/endoabs.63.P577

Comparison of effects of metformin used as a monotherapy or in combination with gliclazide MR on glycemic control and lipid profile in patients with type 2 diabetes mellitus

Snezana Vujosevic1, Sanja Borozan1, Sreten Kavaric1, Olivera Boskovic1, Djordjije Krnjevic1, Elzana Cikic1, Emir Muzurovic1, Igor Bjeladinovic2, Snezana Radovanic3, Rada Sparavalo4, Violeta Vukicevic5, Suzana Ivanovic6 & Enisa Pupovic7


1Clinical Center of Montenegro, Podgorica, Montenegro; 2General Hospital Kotor, Kotor, Montenegro; 3General hospital Berane, Berane, Montenegro; 4General Hospital Niksic, Niksic, Montenegro; 5‘Dr Viva’, Niksic, Montenegro; 6General Hospital Cetinje, Cetinje, Montenegro; 7Primary Health Care Center Podgorica, Podgorica, Montenegro.


Objective: To evaluate and compare the effects of metformin used as a single-agent therapy and in combination with gliclazide modified release (MR) on glycoregulation and lipid profile in patients with type 2 diabetes mellitus (T2DM).

Methodology: A multi-center observational epidemiological study was carried out in patients with T2DM, divided in two groups according to the current type of treatment: first group was on monotherapy with metformin in daily dose (DD) of 2.000 mg while second group was treated with metformin in same DD plus gliclazide MR 60 mg per day. Anthropometric measurements, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) and lipid profile (cholesterol, tryglicerides, HDL, LDL) were evaluated and statistically analyzied.

Results: A total of 105 patients were enrolled of whom 59 (56.2%) were treated with metformin (mean age 59.62 years, range of 40–78 years, SD 9.08; male: female=27:32 patients) while 46 (43.8%) were on combined therapy with metformin plus gliclazide MR (mean age 60.24 years, range of 36–77 years, SD 10.13; male: female=19:27 patients). No significant difference was observed between groups regarding age (t test, P=0.744) and gender (Pearson chi square test, P=0.648). Patients with metformin had higher body mass index (BMI), with mean BMI of 30.74 kg/m2 compared to 27.99 kg/m2 (t test, P=0.004). No significant difference was registrated regarding FPG (t test, P=0.917) and plasma lipids while patients with combined therapy had higher levels of HbA1c (t test, P=0.032) and worse glycoregulation (Pearson chi square test, P=0.021).

Conclusion: In patients with T2DM requiring combination therapy, a tight follow-up through various modalities in needed in order to achive and maintain an adequate glycaemic control.